Today, the Cystic Fibrosis Foundation announced that it awarded funding to enGene Inc. to develop a customized vehicle to deliver genetic-based therapies, such as gene therapy and gene editing, into the lung cells of people with cystic fibrosis (CF). Delivering genetic-based therapies to the lungs is a key hurdle to developing effective treatments for all people with CF, including individuals with two nonsense and rare mutations.
Site Search
Showing 31 - 37 of 37 results
Press Release
|
Oct. 29, 2020
|
4 min read
The Cystic Fibrosis Foundation has awarded up to $3 million to Kinnear Pharmaceuticals to conduct preclinical testing of a broad-spectrum anti-infective that has the potential to treat multi-drug resistant Pseudomonas and other infections in people with cystic fibrosis.
Press Release
|
Jan. 26, 2021
|
3 min read
Press Release
|
March 19, 2015
|
2 min read
Program Aimed at Advancing Search for Therapies Targeting Most Common Mutation of CF
Press Release
|
April 16, 2015
|
3 min read
Press Release
|
March 18, 2015
|
3 min read
New Agreement Increases Potential Payments to EPIX by up to $37.7 Million
Press Release
|
April 7, 2008
|
6 min read
This is an exciting time in cystic fibrosis clinical research. Not only are there several clinical trials of therapies to treat the underlying cause of CF, but there are also many trials to treat key symptoms of CF and improve quality of life. These include studies of antibiotics and anti-inflammatories to treat lung infections and inflammation, as well as treatments to improve nutrition and digestion.